• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本不同严重程度 COVID-19 患者的抗体反应模式。

Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan.

机构信息

Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.

Center for Clinical Infectious Diseases and Research, Saitama Medical University, Saitama, Japan.

出版信息

J Med Virol. 2021 May;93(5):3211-3218. doi: 10.1002/jmv.26899. Epub 2021 Mar 9.

DOI:10.1002/jmv.26899
PMID:33620098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8014305/
Abstract

We analyzed antibody response patterns according to the level of disease severity in patients with novel coronavirus disease 2019 (COVID-19) in Japan. We analyzed 611 serum specimens from 231 patients with COVID-19 (mild, 170; severe, 31; critical, 30). Immunoglobulin M (IgM) and IgG antibodies against nucleocapsid protein (N) and spike 1 protein (S1) were detected by enzyme-linked immunosorbent assays. The peaks of fitting curves for the optical density (OD) values of IgM and IgG antibodies against N appeared simultaneously, while those against S1 were delayed compared with N. The OD values of IgM against N and IgG against both N and S1 were significantly higher in the severe and critical cases than in the mild cases at 11 days after symptom onset. The seroconversion rates of IgG were higher than those of IgM against both N and S1 during the clinical course based on the optimal cut-off values defined in this study. The seroconversion rates of IgG and IgM against N and S1 were higher in the severe and critical cases than in the mild cases. Our findings show that a stronger antibody response occurred in COVID-19 patients with greater disease severity and there were low seroconversion rates of antibodies against N and S1 in the mild cases.

摘要

我们根据日本新型冠状病毒病 2019 患者(COVID-19)疾病严重程度分析了抗体反应模式。我们分析了 231 例 COVID-19 患者(轻症 170 例、重症 31 例、危重症 30 例)的 611 份血清标本。采用酶联免疫吸附试验检测针对核衣壳蛋白(N)和刺突 1 蛋白(S1)的免疫球蛋白 M(IgM)和 IgG 抗体。IgM 和 IgG 针对 N 的光密度(OD)值拟合曲线的峰值同时出现,而针对 S1 的峰值则滞后于 N。与轻症病例相比,在发病后 11 天,重症和危重症病例针对 N 的 IgM 和针对 N 和 S1 的 IgG 的 OD 值明显更高。根据本研究中定义的最佳截断值,IgG 对 N 和 S1 的血清转化率均高于 IgM。N 和 S1 的 IgG 和 IgM 血清转化率在重症和危重症病例中均高于轻症病例。我们的研究结果表明,疾病严重程度较高的 COVID-19 患者的抗体反应更强,且轻症患者针对 N 和 S1 的抗体血清转化率较低。

相似文献

1
Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan.日本不同严重程度 COVID-19 患者的抗体反应模式。
J Med Virol. 2021 May;93(5):3211-3218. doi: 10.1002/jmv.26899. Epub 2021 Mar 9.
2
Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.在日本人群中,不同类别抗体对 SARS-CoV2 感染的反应动力学:IgA 和 IgG 的滴度比 IgM 滴度更早升高。
Int Immunopharmacol. 2022 Feb;103:108491. doi: 10.1016/j.intimp.2021.108491. Epub 2021 Dec 21.
3
Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.日本一种新型自动化化学发光抗SARS-CoV-2 IgM和IgG抗体检测系统的验证,该系统可同时检测N蛋白和S蛋白。
PLoS One. 2021 Mar 4;16(3):e0247711. doi: 10.1371/journal.pone.0247711. eCollection 2021.
4
Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.利用定性和定量免疫诊断检测监测重症 COVID-19 患者的特异性 IgM 和 IgG 产生:一项回顾性队列研究。
Front Immunol. 2021 Sep 3;12:705441. doi: 10.3389/fimmu.2021.705441. eCollection 2021.
5
Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.酶联免疫吸附试验评价 COVID-19 患者血清 IgM 和 IgG 抗体。
J Med Virol. 2021 May;93(5):2857-2866. doi: 10.1002/jmv.26741. Epub 2021 Mar 1.
6
Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.COVID-19 患者在疫情早期对 SARS-CoV-2 抗体的动态变化。
Virol Sin. 2020 Dec;35(6):744-751. doi: 10.1007/s12250-020-00268-5. Epub 2020 Jul 27.
7
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.中国北京一家三级甲等医院中新冠病毒肺炎患者抗体反应的纵向分析
Front Immunol. 2021 Mar 15;12:614436. doi: 10.3389/fimmu.2021.614436. eCollection 2021.
8
Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.采用微阵列和其他 12 种免疫分析法评估急性 SARS-CoV-2 感染中 S1、S2 和 NCP 特异性 IgM、IgA 和 IgG 抗体的动力学。
J Clin Microbiol. 2021 Apr 20;59(5). doi: 10.1128/JCM.02890-20.
9
SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.根据症状严重程度评估 SARS-CoV-2 特异性抗体和 T 细胞应答动力学。
Am J Trop Med Hyg. 2021 Jun 17;105(2):395-400. doi: 10.4269/ajtmh.20-1594.
10
Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.用于特异性 SARS-CoV-2 IgG、IgA 和 IgM 抗体的 ELISA 的分析和临床验证。
J Med Virol. 2021 Feb;93(2):803-811. doi: 10.1002/jmv.26303. Epub 2020 Jul 27.

引用本文的文献

1
National and sub-national sero-epidemiology of immunoglobulin G against SARS-CoV-2 in Iran in 2021.2021年伊朗全国及各地区针对新冠病毒的免疫球蛋白G血清流行病学研究
PLoS One. 2025 Jul 31;20(7):e0313795. doi: 10.1371/journal.pone.0313795. eCollection 2025.
2
Persistence and decay of neutralizing antibody responses elicited by SARS-CoV-2 infection and hybrid immunity in a Canadian cohort.加拿大队列中由新冠病毒感染和混合免疫引发的中和抗体反应的持久性和衰减情况。
Microbiol Spectr. 2025 Apr;13(4):e0133324. doi: 10.1128/spectrum.01333-24. Epub 2025 Feb 19.
3
Associations between ethnicity and persistent physical and mental health symptoms experienced as part of ongoing symptomatic COVID-19.持续出现 COVID-19 症状患者的种族与身心持续性健康症状之间的关联。
PLoS One. 2024 Oct 31;19(10):e0312719. doi: 10.1371/journal.pone.0312719. eCollection 2024.
4
Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.分析B细胞受体库以评估单价奥密克戎XBB.1.5 mRNA疫苗的免疫原性。
EJHaem. 2024 May 29;5(4):661-668. doi: 10.1002/jha2.932. eCollection 2024 Aug.
5
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.新型冠状病毒肺炎(COVID-19)的全面综述:流行病学、发病机制、诊断和检测技术的进展,以及大流行后的治疗策略。
Int J Mol Sci. 2024 Jul 26;25(15):8155. doi: 10.3390/ijms25158155.
6
COVID-19 antibody responses in individuals with natural immunity and with vaccination-induced immunity: a systematic review and meta-analysis.自然免疫个体和接种疫苗诱导免疫个体的 COVID-19 抗体反应:系统评价和荟萃分析。
Syst Rev. 2024 Jul 19;13(1):189. doi: 10.1186/s13643-024-02597-y.
7
A handheld luminometer with sub-attomole limit of detection for distributed applications in global health.一种手持式发光计,检测限可达亚阿托摩尔,适用于全球卫生领域的分布式应用。
PLOS Glob Public Health. 2024 Feb 21;4(2):e0002766. doi: 10.1371/journal.pgph.0002766. eCollection 2024.
8
A stronger antibody response in increased disease severity of SARS-CoV-2.在 SARS-CoV-2 疾病严重程度增加的情况下,抗体反应增强。
BMC Infect Dis. 2024 Jan 2;24(1):17. doi: 10.1186/s12879-023-08923-4.
9
Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study.SARS-CoV-2 感染后抗体反应的纵向分析取决于疾病严重程度:一项前瞻性队列研究。
Viruses. 2023 Nov 13;15(11):2250. doi: 10.3390/v15112250.
10
Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies.抗 SARS-CoV-2 IgG 抗体的非中和功能。
Biomed J. 2024 Feb;47(1):100666. doi: 10.1016/j.bj.2023.100666. Epub 2023 Sep 29.

本文引用的文献

1
Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals.新型冠状病毒肺炎住院患者和无症状感染者体内的抗刺突蛋白、抗核衣壳蛋白抗体及中和抗体
Front Microbiol. 2020 Oct 19;11:584251. doi: 10.3389/fmicb.2020.584251. eCollection 2020.
2
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.冠状病毒抗体介导免疫的系统评价:动力学、保护相关性及与严重程度的关系。
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
3
Not just antibodies: B cells and T cells mediate immunity to COVID-19.不仅是抗体:B 细胞和 T 细胞介导对 COVID-19 的免疫。
Nat Rev Immunol. 2020 Oct;20(10):581-582. doi: 10.1038/s41577-020-00436-4.
4
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
5
SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity.SARS-CoV-2 抗体反应不能预测 COVID-19 疾病严重程度。
Am J Clin Pathol. 2020 Sep 8;154(4):459-465. doi: 10.1093/ajcp/aqaa123.
6
Kinetics of viral load and antibody response in relation to COVID-19 severity.病毒载量和抗体反应动力学与 COVID-19 严重程度的关系。
J Clin Invest. 2020 Oct 1;130(10):5235-5244. doi: 10.1172/JCI138759.
7
High neutralizing antibody titer in intensive care unit patients with COVID-19.COVID-19 重症监护病房患者的高中和抗体滴度。
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670. doi: 10.1080/22221751.2020.1791738.
8
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
9
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.病毒刺突蛋白的受体结合域是 SARS-CoV-2 患者体内抗体的免疫优势和高度特异性靶标。
Sci Immunol. 2020 Jun 11;5(48). doi: 10.1126/sciimmunol.abc8413.
10
Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.在 COVID-19 重症进展患者中观察到延迟的特异性 IgM 抗体反应。
Emerg Microbes Infect. 2020 Dec;9(1):1096-1101. doi: 10.1080/22221751.2020.1766382.